FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

washington, D.C. 2005

OMB APPRO	JVAL
OMB Number:	3235-0287
Estimated average bur	den
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     SCHAFFER DAVID					2. Issuer Name <b>and</b> Ticker or Trading Symbol 4D Molecular Therapeutics Inc. [ FDMT ]									all app Direc	o of Reportin dicable) tor er (give title	ng Pe	10% O	vner		
		AR THERAPE	Middle JTI(	,		3. Date of Earliest Transaction (Month/Day/Year) 09/27/2021								elow)		below)	Other (specify below)			
5858 HORTON STREET #455					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) EMERY	VILLE C	A 9	4608	8											X		filed by One filed by Mor on		Ü	
(City)	(St	ate) (Z	Zip)																	
		Table	I - I	Non-Deriva	tiv	e Secui	rities	Acq	quire	ed, C	Disp	osed o	of, or l	Benef	icially	Own	ed			
Dat			2. Transaction Date (Month/Day/Ye	Execution Dat		n Date,	Tr	3. Transaction Code (Instr. 8)					nd 5)	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership		
								C	ode	v	Am	ount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		(Instr. 4)
Common	Stock			09/27/202	1			5	S <sup>(1)</sup>		13	3,075	D	\$32.5	5871 <sup>(2)</sup>	98	6,925 <sup>(3)</sup>		D	
Common	Stock			09/27/202	1			5	5 <sup>(1)</sup>		6	5,157	D	\$33.5	5115(4)	98	30,768		D	
Common	Stock			09/27/202	1			5	5 <sup>(1)</sup>			100	D	\$3	4.19	98	30,668		D	
Common	Stock			09/28/202	1			5	S <sup>(1)</sup>		1	3,812	D	\$30.5	\$30.5164 <sup>(5)</sup>		966,856		D	
Common	Stock			09/28/202	1			5	S <sup>(1)</sup>			100	D	\$	32	96	66,756		D	
		Tal	ole I	II - Derivati (e.g., pu												Owne	d			
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  3. Transaction Date (Month/Day/Yet)			Exe if ar	Deemed cution Date, ny nth/Day/Year)		nsaction de (Instr.	5. Numbe of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exp	iration	eercisable and n Date ay/Year)		Amo Secu Unde Deriv		Der Sec (Ins	rivative decurity Str. 5) E	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
														Amou or	nt					

## **Explanation of Responses:**

- 1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- 2. The transaction was executed in multiple trades in prices ranging from \$32.09 to \$33.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Date

(D)

Expiration

- 3. Since the date of the reporting person's last ownership report, he transferred 1,000,000 shares of FDMT common stock to his ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-spouse.
- 4. The transaction was executed in multiple trades in prices ranging from \$33.10 to \$34.01, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 5. The transaction was executed in multiple trades in prices ranging from \$30.28 to \$31.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

/s/ August J. Moretti,
Attorney-in-Fact for David 09/29/2021
Schaffer

\*\* Signature of Reporting Person Date

Number

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.